Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trialSTX-478 ...